By Josh Nathan-Kazis
The Food and Drug Administration will only stick to its existing process for updating Covid-19 shots for older adults and those at a high risk of severe illness, the agency's head wrote in a medical journal article on Tuesday.
In order to get new Covid-19 shots approved for younger, healthy adults, drugmakers will need to run new randomized clinical trials, FDA commissioner Dr. Marty Makary wrote.
Though the stance would impose new limits on FDA approvals, it's a softer approach than Trump officials had seemed poised to take. Moderna shares were up 9.4% to $28.85 in midday trading.
This is breaking news. Please check back for more analysis soon.
Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
May 20, 2025 11:55 ET (15:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.